Results 171 to 180 of about 12,266 (204)

PDE5 inhibitors in diabetic peripheral neuropathy

International Journal of Clinical Practice, 2006
openaire   +1 more source

PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges. [PDF]

Front Oncol
Ghoflchi S, Nakhaei A, Abbasinezhad-Moud F, Jalili-Nik M, Cimino PJ.   +4 more
europepmc   +1 more source

Intracavernosal Botulinum Toxin Injection for Erectile Dysfunction: A Comprehensive Systematic Review. [PDF]

Life (Basel)
Talavera Cobo V, Yanez Ruiz CA, Tapia Tapia MD, Calva Lopez A, Muñoz Bastidas CA, Guillen-Grima F, Ancizu Marckert FJ, Labairu Huerta L, Torres Roca M, Diez-Caballero Alonso FJ, Sanchez Zalabardo D, Miñana Lopez B, Robles Garcia JE.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PDE5 Inhibitors and their Applications

Current Medicinal Chemistry, 2010
PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides cAMP and cGMP to the corresponding 5-nucleoside monophosphate. PDE5 takes part in many physiological and pathological functions, therefore selective PDE5 inhibitors are potentially useful for a variety of pathologies.
GIOVANNONI, MARIA PAOLA, VERGELLI, CLAUDIA, A. Graziano, DAL PIAZ, VITTORIO   +3 more
openaire   +3 more sources

Phosphodiesterase Type 5 (PDE5) Inhibitors

2003
Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning, Ulrich, Niewöhner, Erwin, Bischoff   +2 more
openaire   +2 more sources